Table 2.
Multivariate analyses showing hazard ratio for patient RFS conferred by tumor size, nodal status, nuclear grade, vascular invasion, hormone receptor, HER2, B7-H3 expression, Foxp3-positive cell in TILs
| Variable | Hazard ratio | 95 % CI | p valuea |
|---|---|---|---|
| B7-H3 expression (high vs. low) | 5.471 | 1.233–24.269 | 0.025 |
| Foxp3-positive cell in TILs (high vs. low) | 3.416 | 0.929–12.564 | 0.065 |
| Lymphovascular invasion (+ve vs. –ve) | 5.405 | 0.670–43.588 | 0.113 |
| Tumor size (≤2 vs. >2 cm) | 1.798 | 0.449–7.199 | 0.407 |
| Nodal status (+ve vs. –ve) | 1.588 | 0.468–5.390 | 0.458 |
| Nuclear grade (grade 1 vs. grade 2,3) | 0.669 | 0.105–4.259 | 0.671 |
| Hormone receptor (+ve vs. –ve) | 0.779 | 0.192–3.161 | 0.726 |
| HER2 (+ve vs. –ve) | 1.070 | 0.351–3.260 | 0.905 |
RFS recurrence-free survival, HER2 human epidermal growth factor receptor 2, Foxp3 forkhead box P3, TILs tumor-infiltrating lymphocytes, +ve positive, – ve negative, CI confidence interval
aCox’s proportional hazards regression analysis